*Cells* **2020**, *9*, 1476

sensing by RIG-I may open up novel treatment options and limit the severity of ZIKV associated neurological symptoms.

**Author Contributions:** Conceptualization, M.S. and J.R.; methodology, all authors; software, n/a; validation, M.S. and J.R.; formal analysis, M.S. and J.R.; investigation, M.S., A.B., N.G., J.H.; resources, P.H. and A.K.; data curation, M.S. and N.G.; writing—original draft preparation, M.S. and J.R.; writing—review and editing, all authors; visualization, M.S. and N.G.; supervision, J.R.; project administration, J.R.; funding acquisition, J.R. and A.K. All authors have read and agreed to the published version of this manuscript.

**Funding:** This work was funded by the UK Medical Research Council [MRC core funding of the MRC Human Immunology Unit; J.R.], [MC\_UU\_12014/8, MR/N017552/1; A.K.] and by the Wellcome Trust [Grant Number 100954; J.R.]. J.H. is supported by the European Commission under the Horizon2020 program H2020 MSCA-ITN GA 675278 EDGE. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

**Acknowledgments:** We thank members of the Rehwinkel lab for discussion. We thank the Oxford Genomics Center at the Wellcome Center for Human Genetics (funded by Wellcome Trust gran<sup>t</sup> reference 203141/Z/16/Z) for the generation and initial processing of the sequencing data. We further acknowledge G. Kochs, C. Reis e Sousa, R. Randall and A. Merits for their kind gifts of cell lines and antibodies.

**Conflicts of Interest:** The authors declare no conflicts of interest.
